Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
AA imposes a significant financial burden in Saudi Arabia, driven largely by productivity losses and drug acquisition costs. These findings underscore the need for early diagnosis, standardized treatment protocols, and improved access to innovative therapies. Integrated care pathways and national registries are essential to optimize resource allocation and improve patient outcomes.
Authors
- Saad Alsogair
- Ahmed Saeed (ORCID: https://orcid.org/0000-0003-2929-3911)
- Abdulrahman Alturaiki (ORCID: https://orcid.org/0000-0002-8006-8544)
- Mohammad I. Fatani (ORCID: https://orcid.org/0000-0002-7461-0595)
- Khalidah A. Alenzi (ORCID: https://orcid.org/0000-0003-1512-4332)
- Ayman Behiry
- Ali Almomatin
Institutions
- Pfizer (United States) (US)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- Saad Specialist Hospital (SA)
- Saudi Center for Disease Prevention and Control (SA)
- Hera General Hospital (SA)
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2025-12-19
- DOI
- https://doi.org/10.36469/001c.151864
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer